T roponin is the key component of the calciumdependent switch of the contractile apparatus in striated muscle. There are three subunits of troponin: troponin C, a Ca 2ϩ -binding calmodulin-like protein; troponin T, which attaches the complex to tropomyosin, anchoring it to the thin filament as well as having a regulatory role; and troponin I (TnI), named for its ability to inhibit actin-myosin interactions at diastolic levels of Ca 2ϩ . As cytosolic Ca 2ϩ increases in systole, it binds to a regulatory Ca 2ϩ -binding site on TnC, leading to increasing affinity of TnC for TnI and weakening the interactions of TnI and actin. This permits movement of tropomyosin-troponin on the thin filament such that the inhibition of actin-myosin interaction is diminished, increasing the probability of crossbridge cycling and muscle shortening. The ability to inhibit the actin-myosin interaction resides within a 12-amino acid region of the TnI molecule, although its inhibitory function is modulated by other regions of TnI. 1 In mature mammals, a different TnI gene is expressed specifically in each of the three types of striated muscle: fast twitch (fsTnI), slow twitch (ssTnI), and cardiac (cTnI). The fetal and neonatal cardiac atria and ventricle also express ssTnI, and there is a gradual downregulation of the mRNA for ssTnI and increased expression of cTnI with maturation. 2 This gene switch occurs in all mammalian species studied to date, including human. The tight regulation of this process was made apparent when the cTnI gene was subjected to targeted deletion in mice by Huang et al. 3 Rather than persistently maintaining the ssTnI gene expression after its normal developmental stage in the heart, the mice died as this gene was turned off postnatally.
What are the advantages of the expression of ssTnI in the fetal heart? One functional measure of the calcium switch in muscle is the rate of ATP hydrolysis by myofilaments (actin-activated myosin or myofibrillar MgATPase activity), which increases as the available Ca 2ϩ increases up to a maximal saturating level. A similar, although not completely analogous, relationship of steady-state isometric tension development can be measured in skinned muscle fibers exposed to varying Ca 2ϩ concentrations. The presence of ssTnI in the myofilament results in a baseline left shift in this relationship, referred to as Ca 2ϩ sensitization. 4, 5 This is conceivably advantageous in the fetal heart, in which the sarcoplasmic reticulum is poorly developed, and the contractile force is much more dependent on Ca 2ϩ entry through the cell membrane. Another advantage, first noted by Solaro et al 6 before the basis of the TnI isoform shift was known, is that myofibrils from immature heart are resistant to the effect of acidosis on the myofibrillar MgATPase-Ca 2ϩ relation. In contrast, the myofibrillar MgATPase activity of myofibrils isolated from mature heart is significantly desensitized to Ca 2ϩ (ie, right-shifted) when exposed to lower pH, which limits contractile force. Finally, it is notable that the ssTnI isoform lacks the 32-residue amino terminal extension present in cTnI. This region of the molecule contains two adjacent serine residues that are targets of protein kinase A (PKA) phosphorylation. Functionally, PKA phosphorylation desensitizes the myofilament to Ca 2ϩ , although it may also affect crossbridge kinetics allowing more rapid cycling of crossbridges. 7 The lack of these PKA targets on TnI in the fetus coincides temporally with the lack of sympathetic innervation in immature heart. There are also sites for PKC phosphorylation on TnI, some of which differ between the ssTnI and cTnI isoforms. Alterations in phosphorylation of TnI have been implicated in disease states such as dilated cardiomyopathy in mouse models and end-stage heart failure in humans. 8 -10 In this issue of Circulation Research, Westfall and colleagues 11 use a myocyte gene transfer model to examine an apparent paradox that arose from prior studies reporting the expression of TnI variants in the hearts of transgenic mice. Previously, Fentzke et al 5 completely replaced cTnI with ssTnI in adult mouse hearts and found that the mice exhibited some evidence of diastolic dysfunction as well as Ca 2ϩ sensitization of the myofilaments. However, these mice did not have the typical phenotype of hypertrophic cardiomyopathy at the organ level: myocyte disarray and fibrosis were not noted, nor were these hearts hypertrophied. James et al 12 then created mice expressing a TnI mutation that had been noted in a pedigree with familial hypertrophic cardiomyopathy (FHC), cTnI R146G, a mutation in the critical inhibitory region of TnI. Although it could not be measured directly, these mice likely had less than full replacement of the native TnI with the mutant, but despite this, two lines with this mutant had early lethality with grossly abnormal hearts, suggesting dose-dependent lethality. The remaining lines demonstrated varying degrees of cardiac fibrosis, myocyte disarray, diastolic dysfunction, and, in the one line in which it was measured, increased Ca 2ϩ sensitization of tension.
Although there is a spectrum of functional changes produced by individual FHC mutations, 13 several studies have noted increased Ca 2ϩ sensitivity with disease-causing mutations of ␣-tropomyosin, TnT, TnI, and essential myosin light chain. 14 -18 Ca 2ϩ sensitization may result in elevated resting tension and/or impaired relaxation, thus causing diastolic dysfunction. However, the work of Westfall et al 11 makes it clear that, although the disease-related TnI mutant and the fetal cardiac ssTnI isoform both caused increased Ca 2ϩ sensitization of steady-state tension to a similar extent, they result in very different organ-level phenotypes. In general, how a perturbation of myofilament protein function relates to the cellular and clinical phenotype of FHC is a key question that remains largely unanswered. One plausible hypothesis advanced by Westfall et al is that the Ca 2ϩ sensitization associated with ssTnI expression also results in a resilience to the detrimental effect of acidosis, whereas the FHC cTnI R146G mutant myofilaments still become Ca 2ϩ desensitized under acidic conditions. This may be relevant in FHC because of the association of cardiac ischemia in this condition with abnormal intramuscular coronary arteries and myocardial bridging. 19 However, it is important to note that other factors could also mediate the difference in whole-heart phenotype between mice expressing ssTnI and cTnI R146G. Previous in vivo studies of abnormal phosphorylation mutants of TnI uncovered altered twitch kinetics, 20 potentially as a result of altered crossbridge kinetics or feedback of the altered myofilament properties to produce secondary changes in calcium cycling. These types of alterations would not be evident in the steady-state measurements of tension-Ca 2ϩ relationships reported here. Similar perturbations could contribute to the organ-level abnormalities with the cTnI R146G mutation and should ultimately be investigated.
Another interesting finding in the study of Westfall et al 11 is the apparent lower affinity of the cTnI R146G mutant for the myofibrils, as demonstrated by a form of competition assay by viral transduction in the cardiac myocytes. The precise level of protein incorporation of site-specific myofilament protein mutants is often difficult to assess in transgenic overexpression models, indicating the value of the approach used in the present study. 11 Should in vivo gene therapy ultimately be available in clinical care, this work also suggests the concept of "competing" the abnormal protein off the myofilament with virally transduced native cTnI.
In summary, the study of Westfall et al 11 offers some new insight into the relationship between the myofilament function and phenotype in the whole heart. Many additional detailed mechanistic studies are necessary to understand the link between alterations in myofilament proteins and clinical disease in FHC.
